Inhibrx CEO Mark Lappe reports acquisition of 25,000 common shares worth $2.59 million

• Inhibrx Biosciences CEO Mark Lappe reported open-market purchases totaling 25,000 common shares at weighted-average prices of $99.29 to $112.28.
• Holdings in the Lappe Family Trust rose to 730,548 shares following the purchases.
• Separate indirect holdings listed 165,000 shares in a descendants’ trust, plus 54,865 shares in a Roth IRA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001366074-26-000002), on September 08, 2026, and is solely responsible for the information contained therein.